Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Anticoagulants Market by Route of Administration (Oral anticoagulant, Injectable anticoagulant) by Application (Atrial fibrillation & heart attack, Stroke, Deep vein thrombosis (DVT), Pulmonary embolism (PE)) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Anticoagulants Market was valued at USD XX billion in the year 2017. Global Anticoagulants market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023.

In the Global Anticoagulants Market, by region Asia Pacific region holds the highest market share in 2017 and is also market is considered as the fastest growing market in the forecasted period owing to their market demands. At a country level, China and India in Asia-Pacific are projected to grow strongly in the coming years due to continued economic development with developing healthcare infrastructure and improving healthcare awareness.

Drivers:

            Increase in the prevalence of atrial fibrillation, venous thromboembolism, and stroke

Restraints:

            Changing government regulations and norms.

            High price of NOACs

Opportunities:

            Growth opportunities in emerging markets

Challenges:

            Poor demand in underdeveloped countries

The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin and LMWH, vitamin K antagonist, and others. By route of administration, the market is segmented as an oral anticoagulant and injectable anticoagulant. The various application markets are atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others.

Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc., Portola Pharmaceuticals, Inc., and Sanofi S.A. are some of the key players in the Global Anticoagulants market.

Key Benefits for Stakeholders

Anticoagulants Manufacturers, Distributors, and Retailers

Raw material suppliers

Research and Consulting Organization

Healthcare institution and pharmaceutical companies

Investment research firms

By Drug Class

NOACs

            Eliquis

            Bevyxxa

            Xarelto

            Savaysa & lixiana

            Pradaxa

Heparin & LMWH

Vitamin K Antagonist

Others

By Route of Administration

Oral anticoagulant

Injectable anticoagulant

By Application

Atrial fibrillation & heart attack

Stroke

Deep vein thrombosis (DVT)

Pulmonary embolism (PE)

Others

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Aspen Holdings

Bristol-Myers Squibb Company

Bayer AG

GlaxoSmithKline Plc.

Boehringer Ingelheim Pharma GmbH & Co. KG

Daiichi Sankyo Co., Ltd.

Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Pfizer Inc.

Portola Pharmaceuticals, Inc.

Sanofi

(A brief overview of 10 companies is also provided in a report.)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Anticoagulants Market, By Drug Class

6.1 NOACs

            6.1.1 Eliquis

            6.1.2 Bevyxxa

            6.1.3 Xarelto

            6.1.4 Savaysa & lixiana

            6.1.5 Pradaxa

6.2 Heparin & LMWH

6.3 Vitamin K Antagonist

6.4 Others

7. Anticoagulants Market, By Route of Administration

7.1 Oral anticoagulant

7.2 Injectable anticoagulant

8. Anticoagulants Market, By Application

8.1 Atrial fibrillation & heart attack

8.2 Stroke

8.3 Deep vein thrombosis (DVT)

8.4 Pulmonary embolism (PE)

8.5 Others

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. France

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. South Korea

       9.4.2. China

       9.4.3. Japan

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 Aspen Holdings

10.2 Bristol-Myers Squibb Company

10.3 Bayer AG

10.4 GlaxoSmithKline Plc.

10.5 Boehringer Ingelheim Pharma GmbH & Co. KG

10.6 Daiichi Sankyo Co., Ltd.

10.7 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

10.8 Pfizer Inc.

10.9. Portola Pharmaceuticals, Inc.

10.10 Sanofi

(A brief overview of 10 companies is also provided in a report)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports